MedTechs Adjust 2025 Outlook Amid Tariffs: What Investors Need to Know

After two strong years, 2025 was expected to mark another high-growth chapter for the MedTech industry, particularly in health technology. Instead, recent first-quarter results show a different story. Rising tariffs and unstable capital markets have changed the game, forcing companies across the board, from startups to large corporations, to adjust their expectations.The re-emergence of aggressive U.S. trade policies under President Donald Trump, highlighted by a 145% baseline tariff on Chinese imports and ...